In the setting of NSCLC, a retrospective analysis of four randomized phase 3 trials failed to demonstrate differential benefit with vandetanib in patients with RET amplifications or copy number gains when compared to the RET wild-type population [87]. The gene discussed is RET; the disease is non-small cell lung carcinoma.